跳至主要内容
临床试验/EUCTR2018-001618-13-PL
EUCTR2018-001618-13-PL进行中(未招募)1 期

Study to Evaluate Arthroplasty Specimens in the Phase 3 Fasinumab Program for Osteoarthritis of the Knee and Hip

Regeneron Pharmaceuticals, Inc.0 个研究点目标入组 50 人开始时间: 2018年11月28日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Previously randomized to R475-PN-1523, R475-OA-1611, or R475-OA-1688 and received at least 1 dose of study drug
  • 2. Notified the site that they are planning a knee or hip arthroplasty during the parent study between randomization and 24 weeks after the last dose of SC study drug
  • 3. Patient’s surgeon/pathologist is willing to coordinate with the site regarding preparation, storage, and shipping of joint tissue samples collected during arthroplasty surgery
  • 4. Willing and able to comply with clinic visits and study-related procedures
  • 5. Provide informed consent signed by study patient or legally acceptable representative
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 25
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 25

排除标准

  • There are no exclusion criteria for this study.

研究者

相似试验